Semaglutide vs Tirzepatide for Mothers

Two molecules, four brand names

Semaglutide is a GLP-1 receptor agonist — it activates one receptor, the one the gut's own incretin hormone uses after a meal. Tirzepatide activates two: the GLP-1 receptor and the GIP receptor together. Both slow gastric emptying, blunt appetite and improve how the body handles glucose, which is why either can help when insulin resistance is what is driving the weight.

Four brand names sit on top of those two molecules. Semaglutide is sold as Wegovy for weight management and Ozempic for type 2 diabetes; tirzepatide is Zepbound for weight management and Mounjaro for diabetes. This page is about the molecules and the trials behind them. If the decision in front of you is really about the branded products — which forms exist, what they cost, what insurance covers — that is Zepbound vs Wegovy.

What each one does alone, with the placebo arm attached

The two figures everyone quotes are "about 15%" for semaglutide and "about 20%" for tirzepatide. Both are roughly right and both are close to useless on their own, because a placebo group on the same lifestyle program loses weight too, and the size of that background loss is what tells you how much of the headline belongs to the drug.

STEP 1 randomized 1,961 adults with obesity and without diabetes to semaglutide 2.4 mg weekly or placebo for 68 weeks. Mean weight change was −14.9% with semaglutide against −2.4% with placebo — a treatment difference of 12.4 percentage points¹. SURMOUNT-1 randomized 2,539 comparable adults to one of three tirzepatide doses or placebo for 72 weeks: −15.0%, −19.5% and −20.9% at 5 mg, 10 mg and 15 mg, against −3.1% with placebo².

One caution about STEP 1, because the numbers most often lifted from it are the responder rates rather than the mean. The trial reported that 86.4% of the semaglutide group lost at least 5%, 69.1% at least 10% and 50.5% at least 15%. Those percentages rest on the roughly 1,212 participants with a week-68 measurement, not on the 1,306 randomized to semaglutide¹. That is a completer denominator, and it flatters the drug a little. The mean change is the more honest single number to carry around.

The one trial that put them in the same room

For years this comparison was cross-trial arithmetic, which is not evidence — different populations, different durations, different years. SURMOUNT-5 fixed that. It randomized 751 adults with obesity and without type 2 diabetes, 1:1, to the maximum tolerated dose of tirzepatide (10 or 15 mg) or of semaglutide (1.7 or 2.4 mg), for 72 weeks. Mean weight change was −20.2% with tirzepatide against −13.7% with semaglutide, and waist circumference fell 18.4 cm against 13.0 cm. Tirzepatide was superior on both endpoints³.

Two caveats belong beside that result rather than buried under it. The trial was open-label — every participant knew which drug they were taking, which can move a weight endpoint through effort as well as pharmacology — and it was funded by tirzepatide's manufacturer. Neither undoes a 6.5-percentage-point gap. Both are why "superior" is a statement about a trial rather than a promise about a person.

The diabetes head-to-head, and the asterisk on it

SURPASS-2 is frequently cited as a second head-to-head. It compared tirzepatide at 5, 10 and 15 mg with semaglutide in 1,879 adults with type 2 diabetes over 40 weeks; tirzepatide beat semaglutide on HbA1c at every dose and produced 1.9 kg, 3.6 kg and 5.5 kg more weight loss respectively⁴. The asterisk is the dose. Semaglutide was given at 1 mg — the diabetes dose, well under the 2.4 mg used for weight management. So SURPASS-2 answers a diabetes question at diabetes dosing. SURMOUNT-5 is the trial that answers the obesity one.

What each molecule does when you stop

Both are studied as ongoing treatment, and both were tested by withdrawal rather than by assertion. In STEP 4, participants who had already lost a mean 10.6% during a 20-week run-in were randomized to continue semaglutide or switch to placebo; over the following 48 weeks the continued group lost a further 7.9% while the placebo group gained 6.9%⁵. SURMOUNT-4 ran the same design for tirzepatide after a 36-week lead-in: continuing produced a further 5.5% reduction, withdrawing produced a 14.0% regain⁶.

Read together those two trials say something more useful than either efficacy headline. Neither molecule is a course you finish. For a mother weighing a medication around a life that may include another pregnancy, the question worth putting to a clinician is what a planned pause actually looks like — which our guide to coming off a GLP-1 works through.

Where the molecules genuinely differ for a mother

Three differences live in the prescribing information rather than in the trials, and none of them is symmetrical.

• Oral contraception. In a combined-pill interaction study, a single 5 mg dose of tirzepatide cut peak ethinyl estradiol concentration by 59% and total exposure by 20%. The Zepbound label therefore tells patients using oral hormonal contraceptives to switch to a non-oral method or add a barrier method for 4 weeks after starting and 4 weeks after each dose increase⁷. The Wegovy prescribing information carries no contraception advice whatsoever — read in full, the word does not appear anywhere in it⁸. If you rely on the pill, that asymmetry is worth more than a percentage point of weight loss.
• Clearing the drug before a pregnancy. Semaglutide's half-life is about a week, and the Wegovy label instructs patients to stop at least 2 months before a planned pregnancy⁸. Tirzepatide's half-life is about 5 days, and the Zepbound label sets no pre-pregnancy interval at all — it says only to discontinue when a pregnancy is recognized⁷. "They both wash out in about a week, so the timing is the same" is a tidy line and a false one: the two labels do not give the same instruction.
• Nursing. Zepbound's label reports an actual human lactation study — 11 lactating adults, a single 5 mg dose, tirzepatide undetectable in 164 of 171 milk samples and under 0.02% of the maternal dose in the rest⁷. The Wegovy injection label states plainly that there are no human milk data for subcutaneous semaglutide⁸. More measurement is not the same thing as clearance to nurse; our guide to GLP-1s and breastfeeding works through what each label actually permits.

If the asymmetries above make you want both molecules on one account rather than committing upfront, five compounded programs verified in August 2026 put both on the same intake: NiceRx at $199/mo semaglutide and $299/mo tirzepatide once the first-month promo ends; RxION Health at the same $199/$299 flat rate; Concierge MD LA, which uniquely also carries brand Ozempic and Wegovy at $1,999/mo for a mother who eventually wants the FDA-approved product instead; MyStart Health, a single flat $299/mo covering either drug; and Lyfe Rx, which lists both at $225 and $299/mo but carries its own FDA warning letter (September 2025) for misleading claims about those same two products — worth reading before its price does the deciding for you.

Three more, checked the same way this pass: Care Clinics prices both at $100/$133 on its 3-month plans, the cheapest pairing in this batch, though it names no pharmacy. Elara Health and Wellness prices both at $183/$268 with quarterly labs and coaching bundled in. Spry prices both at $199/$299 — a number that, unlike the others above, only surfaces from the site's own compiled JavaScript rather than the visible page.

LIV by WellNow offers semaglutide only, no tirzepatide.

How settled is any of this

On average weight loss, the evidence here is about as strong as obesity pharmacology currently gets: one adequately powered randomized head-to-head, consistent with two large placebo-controlled trials and two withdrawal trials pointing the same way. Tirzepatide does more, on average, over about 72 weeks. That much you can rely on.

What the same evidence cannot tell you is where one person lands, because SURMOUNT-5 reports group means and says nothing about who falls above or below them. And on the mother-specific questions the research is thinner by an order of magnitude: the contraception, pre-pregnancy and lactation differences above come from label pharmacology and small interaction studies, not from trials designed around mothers. A trial that randomized women by contraceptive method, or followed them through a planned pause for a pregnancy, would move this page. None has been run. Take your own history — what you take, what you plan — to a clinician, because that is precisely the part the trials skipped.